spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Editorial

Jasmin Collier

Advertising

Max Garry 

 

 
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
Drug Discovery
NDA Groupís Beatriz Lima tells us that the advent of innovative technology that supports the identification of cellular responses could help to renew molecular biology studies, and tackle ongoing research concerns.
INDUSTRY DYNAMICS
The UKís decision to leave the EU has caused many pharma companies to reconsider their position within the sector. Industry advisor Emile Bellott looks into the impact the referendum result may have on these organisations.
  CELL-BASED RESEARCH
Patrick Harrison at University College Cork reveals that a breakthrough has been made: stem cell and gene-editing research could accelerate finding a cure for a variety of disease-causing mutations, as well as enabling tailored treatment.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


 

Industry Events

World Orphan Drug Congress USA 2017

19-21 April 2017, Washington Mariott Wardman Park, Washington, DC.

THE GLOBAL ORPHAN DRUG CONFERENCE AND EXPO IS BACKOver its 7-year history, the shape of the World Orphan Drug Congress USA has changed from a small conference focused on the US market, to a 4 track event, with over 1,000 global attendees, coming together to discuss the latest trends.
More info >>

 
News and Press Releases

Mission Therapeutics Appoints Colin Goddard as Chairman


More info >>

air transport logo

 

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement